Developer docs
API playgroundTry for free, no card

Search company profiles

LakePharma

Full company profile

uuid0002hwg

Namestring
LakePharma
Websiteurl
lakepharma.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

LakePharma is a biologics Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated services from target discovery through engineering, process development, and GMP manufacturing. Founded in 2009 by Hua Tu and headquartered in Belmont, California, the company built its platform around antibody discovery and engineering, recombinant protein and antibody production, cell line development, upstream and downstream process development, and GMP drug substance manufacturing using mammalian, mRNA, and Baculovirus Expression Vector System (BEVS) modalities. Its discovery capabilities include molecular biology, cell engineering, bioanalytical assays, and biological and functional assays, while its development and manufacturing footprint covers cell line development, mRNA process and analytical services, LNP formulation, GMP mammalian and mRNA drug substance manufacturing, analytical testing and release, quality systems, and biorepository services.

The business operates as a B2B fee-for-service CRDMO serving biotech and pharmaceutical developers, monetizing through project-based contracts spanning discovery programs, process development work, and GMP manufacturing campaigns. Following a $30 million funding round in December 2017 led by Summit Partners with participation from Ampersand Capital Partners, the company expanded capabilities both organically and through the March 2016 acquisition of Blue Sky Biotech. LakePharma is now operated within Curia Global, Inc., with the combined biologics offering delivered through the curiaglobal.com biologics division, giving customers access to a broader small molecule, sterile drug product, and analytical testing portfolio alongside the legacy LakePharma biologics stack. Leadership comprises founder/CEO Hua Tu, Chief Scientific Officer Norm Garceau, and CFO Dave Boyle.

Short descriptiontext

LakePharma is a biologics CRDMO providing integrated antibody discovery, cell line development, process development, and GMP manufacturing services, now operating within Curia Global's biologics division serving biotech and pharma developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBelmont, United States
HQ citystring
Belmont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biologics contract manufacturing, antibody discovery services, GMP drug substance manufacturing, recombinant protein production, mRNA process development
Industry6 codes
1Process Development & Tech Transfer (Upstream/Downstream/MSAT)
CodeHLAGAGAEPrimaryYes
2GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
CodeHLAGAGALPrimaryNo
3mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
CodeHLAGAGACPrimaryNo
4Cell Banking & Viral Seed Services (MCB/WCB/VSB)
CodeHLAGAGADPrimaryNo
5Process Development & Tech Transfer Services (upstream/downstream)
CodeHLAAAKAFPrimaryNo
6CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
CodeHLAIALADPrimaryNo
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biologics Contract Development and Manufacturing Services (CRDMO)
Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LakePharma is a biologics CRDMO that provides integrated solutions spanning antibody discovery and engineering, recombinant protein and antibody production, mammalian and mRNA process development, cell line development, LNP formulation, and GMP drug substance and sterile drug product manufacturing. Services are sold to biotech and pharmaceutical developers on a contracted, project-by-project basis, with supporting analytical testing, bioanalytical assays, and quality/release systems. The company is presented under the Curia Global brand, extending the offering into small molecule discovery, development, and generic API supply.

Differentiator
Functional benefit
Problem solved
Product and service5 records
1Biologics Discovery Services
2Biologics Development Services
CategoryBiologics Process Development
Description

Process development services for mammalian biologics (cell line development, upstream and downstream process development), mRNA (DNA services, mRNA process development, mRNA analytical services), and BEVS-based production, supporting IND-enabling development for biologic and nucleic acid programs.

3Biologics GMP Manufacturing
CategoryBiologics GMP Manufacturing
Description

GMP manufacturing services for mammalian drug substance, mRNA, and LNP-formulated nucleic acid drug substance, supported by analytical testing and release, quality systems, and biorepository services for clinical and commercial supply.

4Sterile Drug Product Manufacturing
CategorySterile Fill-Finish Manufacturing
Description

Drug product development (formulation and process development), clinical manufacturing, and commercial manufacturing of sterile biologics drug product for biotech and pharma clients.

5Analytical Testing Services
CategoryAnalytical Testing
Description

Analytical testing services including batch release and stability testing, method development and validation, and solid state chemistry, sold to biologic and small molecule developers.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Catalent
TypeDirect peer
Description

Major global biologics CDMO offering cell line development, process development, and GMP manufacturing for mAbs and newer modalities. Directly comparable to LakePharma's biologics CRDMO scope, but at significantly larger scale.

2Samsung Biologics
TypeDirect peer
Description

Large-scale mammalian biologics CDMO providing cell line development, process development, and commercial GMP manufacturing. Comparable end-to-end biologics service offering, with substantially greater production capacity.

3Lonza
TypeDirect peer
Description

Global leader in biologics CDMO services spanning mammalian cell line development, upstream/downstream process development, and GMP manufacturing. Closely aligned with LakePharma's integrated CRDMO value proposition.

4WuXi Biologics
TypeDirect peer
Description

Full-service biologics CRDMO offering discovery, development, and GMP manufacturing globally. Direct competitor across LakePharma's antibody discovery, cell line, and GMP mammalian service lines.

5AGC Biologics
TypeDirect peer
Description

Mammalian and microbial biologics CDMO with cell line development, process development, and GMP manufacturing services. Highly comparable mid-to-large scale peer for LakePharma's integrated offering.

6Rentschler Biopharma
TypeDirect peer
Description

European-headquartered biologics CDMO offering cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins. Comparable CRDMO model to LakePharma with similar mid-market positioning.

7Abzena
TypeDirect peer
Description

Biologics CDMO focused on antibody discovery, cell line development, process development, and GMP manufacturing. Closely overlaps LakePharma's discovery-to-development offering, with comparable size.

8Aldevron
TypeDirect peer
Description

Biologics services provider specializing in plasmid DNA, mRNA, and protein production for therapeutic developers. Comparable emerging-modality capabilities (mRNA, nucleic acids) to LakePharma's biologics services.

9BioReliance (Merck KGaA)
TypeBroad incumbent
Description

Merck KGaA's biologics testing, validation, and manufacturing services arm. Overlaps with LakePharma's analytical testing, validation, and biomanufacturing support functions within a much broader life-sciences portfolio.

10Curia Global
TypeBroad incumbent
Description

Acquirer/parent platform of LakePharma offering small molecule, sterile fill-finish, and biologics services. Directly comparable biologics CDMO capabilities with broader small-molecule and sterile DP reach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LakePharma

Biologics Contract Development and Manufacturing Services (CRDMO)lakepharma.com

LakePharma is a biologics CRDMO providing integrated antibody discovery, cell line development, process development, and GMP manufacturing services, now operating within Curia Global's biologics division serving biotech and pharma developers.

What LakePharma does

LakePharma is a biologics Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated services from target discovery through engineering, process development, and GMP manufacturing. Founded in 2009 by Hua Tu and headquartered in Belmont, California, the company built its platform around antibody discovery and engineering, recombinant protein and antibody production, cell line development, upstream and downstream process development, and GMP drug substance manufacturing using mammalian, mRNA, and Baculovirus Expression Vector System (BEVS) modalities. Its discovery capabilities include molecular biology, cell engineering, bioanalytical assays, and biological and functional assays, while its development and manufacturing footprint covers cell line development, mRNA process and analytical services, LNP formulation, GMP mammalian and mRNA drug substance manufacturing, analytical testing and release, quality systems, and biorepository services.

The business operates as a B2B fee-for-service CRDMO serving biotech and pharmaceutical developers, monetizing through project-based contracts spanning discovery programs, process development work, and GMP manufacturing campaigns. Following a $30 million funding round in December 2017 led by Summit Partners with participation from Ampersand Capital Partners, the company expanded capabilities both organically and through the March 2016 acquisition of Blue Sky Biotech. LakePharma is now operated within Curia Global, Inc., with the combined biologics offering delivered through the curiaglobal.com biologics division, giving customers access to a broader small molecule, sterile drug product, and analytical testing portfolio alongside the legacy LakePharma biologics stack. Leadership comprises founder/CEO Hua Tu, Chief Scientific Officer Norm Garceau, and CFO Dave Boyle.

LakePharma firmographics

Firmographics
Name
LakePharma
Website
https://lakepharma.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
LakePharma is a biologics CRDMO providing integrated antibody discovery, cell line development, process development, and GMP manufacturing services, now operating within Curia Global's biologics division serving biotech and pharma developers.
Ownership category
akta.pro rank

LakePharma industry classification

Industry
Product category
Biologics Contract Development and Manufacturing Services (CRDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)
akta.pro secondary industries
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

  • Biologics contract manufacturing
  • Antibody discovery services
  • GMP drug substance manufacturing
  • Recombinant protein production
  • MRNA process development

Where LakePharma is headquartered

Location

Headquarters

HQ city
Belmont
HQ country
United States
HQ region
North America

Markets served

LakePharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

LakePharma product offering

Product offering

Core offering

LakePharma is a biologics CRDMO that provides integrated solutions spanning antibody discovery and engineering, recombinant protein and antibody production, mammalian and mRNA process development, cell line development, LNP formulation, and GMP drug substance and sterile drug product manufacturing. Services are sold to biotech and pharmaceutical developers on a contracted, project-by-project basis, with supporting analytical testing, bioanalytical assays, and quality/release systems. The company is presented under the Curia Global brand, extending the offering into small molecule discovery, development, and generic API supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biologics Discovery Services
  • Biologics Development Services Process development services for mammalian biologics (cell line development, upstream and downstream process development), mRNA (DNA services, mRNA process development, mRNA analytical services), and BEVS-based production, supporting IND-enabling development for biologic and nucleic acid programs.
  • Biologics GMP Manufacturing GMP manufacturing services for mammalian drug substance, mRNA, and LNP-formulated nucleic acid drug substance, supported by analytical testing and release, quality systems, and biorepository services for clinical and commercial supply.
  • Sterile Drug Product Manufacturing Drug product development (formulation and process development), clinical manufacturing, and commercial manufacturing of sterile biologics drug product for biotech and pharma clients.
  • Analytical Testing Services Analytical testing services including batch release and stability testing, method development and validation, and solid state chemistry, sold to biologic and small molecule developers.

Companies that use LakePharma

Customer profile

Ideal customer profiles2 records

LakePharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LakePharma partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights5 records

LakePharma competitors and assessment

Company assessment

Direct peers

  • Catalent: Major global biologics CDMO offering cell line development, process development, and GMP manufacturing for mAbs and newer modalities. Directly comparable to LakePharma's biologics CRDMO scope, but at significantly larger scale.
  • Samsung Biologics: Large-scale mammalian biologics CDMO providing cell line development, process development, and commercial GMP manufacturing. Comparable end-to-end biologics service offering, with substantially greater production capacity.
  • Lonza: Global leader in biologics CDMO services spanning mammalian cell line development, upstream/downstream process development, and GMP manufacturing. Closely aligned with LakePharma's integrated CRDMO value proposition.
  • WuXi Biologics: Full-service biologics CRDMO offering discovery, development, and GMP manufacturing globally. Direct competitor across LakePharma's antibody discovery, cell line, and GMP mammalian service lines.
  • AGC Biologics: Mammalian and microbial biologics CDMO with cell line development, process development, and GMP manufacturing services. Highly comparable mid-to-large scale peer for LakePharma's integrated offering.
  • Rentschler Biopharma: European-headquartered biologics CDMO offering cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins. Comparable CRDMO model to LakePharma with similar mid-market positioning.
  • Abzena: Biologics CDMO focused on antibody discovery, cell line development, process development, and GMP manufacturing. Closely overlaps LakePharma's discovery-to-development offering, with comparable size.
  • Aldevron: Biologics services provider specializing in plasmid DNA, mRNA, and protein production for therapeutic developers. Comparable emerging-modality capabilities (mRNA, nucleic acids) to LakePharma's biologics services.

Broad incumbents

  • BioReliance (Merck KGaA): Merck KGaA's biologics testing, validation, and manufacturing services arm. Overlaps with LakePharma's analytical testing, validation, and biomanufacturing support functions within a much broader life-sciences portfolio.
  • Curia Global: Acquirer/parent platform of LakePharma offering small molecule, sterile fill-finish, and biologics services. Directly comparable biologics CDMO capabilities with broader small-molecule and sterile DP reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

LakePharma social profiles

Digital presence

LakePharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LakePharma leadership team

Management profile

Number of profiles

Profiles3 records

LakePharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LakePharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LakePharma

What does LakePharma do?

LakePharma is a biologics CRDMO that provides integrated solutions spanning antibody discovery and engineering, recombinant protein and antibody production, mammalian and mRNA process development, cell line development, LNP formulation, and GMP drug substance and sterile drug product manufacturing. Services are sold to biotech and pharmaceutical developers on a contracted, project-by-project basis, with supporting analytical testing, bioanalytical assays, and quality/release systems. The company is presented under the Curia Global brand, extending the offering into small molecule discovery, development, and generic API supply.

When was LakePharma founded?

LakePharma was founded in 2009. It employs 101 to 250 people.

Where is LakePharma based?

LakePharma is headquartered in Belmont, United States, in the North America region.

Who are LakePharma's main competitors?

Direct peers on record are Catalent, Samsung Biologics, Lonza, WuXi Biologics, AGC Biologics, Rentschler Biopharma, Abzena and Aldevron. Broad incumbents are BioReliance (Merck KGaA) and Curia Global.

Does LakePharma have an API?

No public API is recorded for LakePharma.

What industry is LakePharma in?

LakePharma's product category is Biologics Contract Development and Manufacturing Services (CRDMO). Its primary akta.pro industry code is HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT), with a secondary code of HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCuria Completes Acquisition of LakePharmaCuria has completed its acquisition of LakePharma, a privately held biologics drug discovery and manufacturing organization. This transaction integrates LakePharma's capabilities into Curia's Research and Development division, allowing the combined entity to offer end-to-end solutions for large and small molecules from discovery through commercial manufacturing. LakePharma will operate under the Curia brand while retaining its name temporarily.CuriaglobalCuria to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for BiologicsCuria has entered into a definitive agreement to acquire LakePharma, a biologics drug discovery and manufacturing organization with operations in the United States. This acquisition is intended to expand Curia's end-to-end R&D capabilities and scale for biologics, complementing its recent agreement to acquire Integrity Bio. The transaction is expected to close in the third quarter of the year.PR NewswireCuria to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for BiologicsCuria has entered into a definitive agreement to acquire LakePharma, a biologics drug discovery and manufacturing organization, to expand its end-to-end R&D capabilities. The transaction, expected to close in the third quarter, will combine LakePharma's six facilities and 235 employees with Curia's global network of 21 sites. This acquisition is part of Curia's broader strategy to deepen its biologics offerings, coinciding with a separate agreement to acquire Integrity Bio.VentureBeatCuria to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for BiologicsCuria has entered into a definitive agreement to acquire LakePharma, a U.S.-based biologics drug discovery and manufacturing organization, to expand its end-to-end R&D capabilities. The acquisition will combine LakePharma's six facilities and 235 employees with Curia's existing operations, creating a larger entity capable of offering integrated solutions for both small and large molecules. The transaction is expected to close in the third quarter of 2021, though financial terms were not disclosed.PR NewswireAkston Biosciences and LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 VaccineAkston Biosciences and LakePharma announced a strategic partnership for LakePharma to manufacture commercial quantities of Akston's adjuvated COVID-19 vaccine candidate AKS-452, which is scheduled to begin Phase 1/2 clinical testing later in January 2021. The vaccine is a Fc fusion protein engineered to be shelf-stable for weeks at up to 37 degrees Celsius, enabling distribution without cold-chain infrastructure, with a single 2,000-liter production train capable of producing over one billion doses per year. AKS-452 targets the Receptor Binding Domain of the SARS-CoV-2 spike protein and uses conventional antibody manufacturing techniques.PR NewswireLakePharma Supplying Mount Sinai with SARS-CoV-2 Proteins for Serological AssaysLakePharma announced on May 6, 2020, that it will supply Mount Sinai Health System with recombinant SARS-CoV-2 spike proteins for use in serological antibody blood tests to detect COVID-19 infection. The proteins are produced using LakePharma's proprietary TunaCHO™ manufacturing platform, achieving high purity and yield, with Mount Sinai reporting good results with the reagents. This partnership aims to facilitate broad serologic testing as part of the ongoing response to the COVID-19 pandemic.PR NewswireLakePharma Provides Recombinant COVID-19 Proteins to Facilitate Antibody And Diagnostic Development Against COVID-19LakePharma announced on March 31, 2020 that it has produced recombinant COVID-19 spike proteins using its proprietary TunaCHO™ manufacturing platforms, including full-length ectodomain variants in trimeric form. The company is making these purified proteins available to the biotech community under relaxed business terms to facilitate rapid antibody and diagnostic development against COVID-19. LakePharma, operating as an essential business exempt from stay-at-home orders, has been collaborating with partners on COVID-19 approaches since late January.PR NewswireLakePharma and NJ Bio Form Strategic Alliance to Provide Streamlined Antibody-Drug Conjugate ServicesLakePharma, Inc. and NJ Biopharmaceuticals LLC (NJ Bio) have formed a strategic alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for biotechnology and pharmaceutical clients. Under the agreement, LakePharma will manufacture and supply antibodies as starting materials while NJ Bio handles linker-payload synthesis and bioconjugation, creating a single integrated workflow. The partnership aims to make therapeutic ADC manufacturing more efficient in both time and expense by combining complementary service offerings.PR NewswireLakePharma Announces Its 2019 Symposium AgendaLakePharma announced the theme and agenda for its 2019 annual symposium, titled 'Next-Generation Therapeutics,' scheduled for October 10 in South San Francisco. The event will feature presentations by industry leaders from organizations such as GE Healthcare, UCSF, and REGENXBIO regarding advances in cell and gene therapies.PR NewswireLakePharma Announces Expansion into the Dallas/Fort Worth MetroplexLakePharma, Inc., a US-based biologics CRDMO, announced the opening of a new office in Dallas, Texas on July 23, 2019. The expansion marks the company's entry into the Dallas/Fort Worth Metroplex, bringing its total footprint to three US locations alongside existing facilities in California and Massachusetts. The new Dallas site is intended to improve coordination of client services and enhance customer accessibility through a centralized support team, as demand for integrated biologics services continues to grow.